News and Trends 2 May 2023
FDA fast track for Memo’s kidney transplant infection treatment
Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that…